Compare Comcast Corporation (CMCSA) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comcast Corporation vs Inovio Pharmaceuticals Inc — how do they compare? Comcast Corporation trades at $23.3 (market cap $82.84B), while Inovio Pharmaceuticals Inc trades at $1.19 (market cap $95.85M). The key difference: Comcast Corporation is far larger — about 864.3× Inovio Pharmaceuticals Inc's market cap, and Comcast Corporation pays a 5.69% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CMCSA | INO | |
|---|---|---|
Market Cap | $82.84B | $95.85M |
Sector | Media | Health |
52-Week High | $33.81 | $2.87 |
52-Week Low | $22.32 | $1.05 |
Enterprise Value | $167.98B | $66.86M |
Dividend Yield | 5.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comcast (CMCSA) trades at $23.97, up 1.7% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 16.16% net margin and attractive valuation metrics including P/E of 4.7 and P/B of 0.97. Recent quarterly earnings consistently beat expectations, while strategic moves include the NBCUniversal spin-off and Sky's acquisition of ITV's media unit for $2.14 billion.
The stock presents compelling value with significant upside to the $29.94 consensus target. However, investors face risks from Starlink competition and integration challenges from recent acquisitions. Wall Street maintains strong buy sentiment with 58% analyst support, but execution risks and sector disruption threats warrant careful monitoring.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
